TY - JOUR T1 - Safety update: dupilumab and ocular adverse reactions JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 6 LP - 6 DO - 10.1136/dtb.2022.000073 VL - 61 IS - 1 A2 - , Y1 - 2023/01/01 UR - http://dtb.bmj.com/content/61/1/6.abstract N2 - Overview of: Medicines and Healthcare products Regulatory Agency. Dupilumab (Dupixentâ–¼): risk of ocular adverse reactions and need for prompt management. Drug Safety Update 2022;16(4): 1. ER -